



(86) Date de dépôt PCT/PCT Filing Date: 2005/03/22
(87) Date publication PCT/PCT Publication Date: 2005/09/29
(85) Entrée phase nationale/National Entry: 2006/07/07
(86) N° demande PCT/PCT Application No.: SE 2005/000412
(87) N° publication PCT/PCT Publication No.: 2005/090341
(30) Priorité/Priority: 2004/03/22 (SE0400708-4)


(51) Cl.Int./Int.Cl. *C07D 453/00* (2006.01),
A61P 35/00 (2006.01), *A61K 31/439* (2006.01),
C07D 453/02 (2006.01)

(71) Demandeur/Applicant:
APREA AB, SE

(72) Inventeurs/Inventors:
WESTMAN, JACOB, SE;
WIMAN, KLAS, SE;
SELIVANOVA, GALINA, SE;
BYKOV, VLADIMIR, SE

(74) Agent: SMART & BIGGAR

(54) Titre : DERIVE D'AZABICYCLOOCTANE-3-ONE ET UTILISATION CORRESPONDANTE
(54) Title: AZABICYCLOOCTAN-3-ONE DERIVATIVES AND USE THEREOF



(57) **Abrégé/Abstract:**

Compounds of Formula (I) processes for preparing them, pharmaceutical compositions comprising them. The use of compounds of formula (I) for hyperproliferative diseases, e.g. cancer as well as autoimmune diseases and heart diseases.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number
WO 2005/090341 A1

- (51) International Patent Classification⁷: C07D 453/00, 453/02, A61K 31/439, A61P 35/00
- (21) International Application Number: PCT/SE2005/000412
- (22) International Filing Date: 22 March 2005 (22.03.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0400708-4 22 March 2004 (22.03.2004) SE
- (71) Applicant (for all designated States except US): APREA AB [SE/SE]; c/o Karolinska Innovations AB, Fogdevreten 2B, S-171 77 Stockholm (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): WESTMAN, Jacob [SE/SE]; Ålands-Västerby, S-740 20 Vänge (SE). WIMAN, Klas [SE/SE]; Majvägen 20, S-187 51 Täby (SE). SELIVANOVA, Galina [RU/SE]; Hagalundsgatan 44, S-169 64 Solna (SE). BYKOV, Vladimir [RU/SE]; Runslingan 37, S-187 72 Täby (SE).
- (74) Agent: DR LUDWIG BRANN PATENTBYRÅ AB; P.O.Box 17192, S-104 62 Stockholm (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AZABICYCLOOCTAN-3-ONE DERIVATIVES AND USE THEREOF



(57) Abstract: Compounds of Formula (I) processes for preparing them, pharmaceutical compositions comprising them. The use of compounds of formula (I) for hyperproliferative diseases, e.g. cancer as well as autoimmune diseases and heart diseases.

WO 2005/090341 A1

Azabicyclooctan-3-one derivatives and use thereof

Field of the invention

The present invention relates to azabicyclooctan-3-one derivatives and to the use thereof in therapy. More particularly, the present invention relates to azabicyclooctan-3-one derivatives for the treatment of disorders and diseases such as, for example cancer, autoimmune diseases and heart diseases.

Background of the invention

The most common target for mutations in tumors is the p53 gene. The fact that around half of all human tumors carry mutations in this gene is solid testimony as to its critical role as tumor suppressor. p53 halts the cell cycle and/or triggers apoptosis in response to various stress stimuli, including DNA damage, hypoxia, and oncogene activation (Ko and Prives, 1996; Sherr, 1998). Upon activation, p53 initiates the p53-dependent biological responses through transcriptional transactivation of specific target genes carrying p53 DNA binding motifs. In addition, the multifaceted p53 protein may promote apoptosis through repression of certain genes lacking p53 binding sites and transcription-independent mechanisms as well (Bennett *et al.*, 1998; Gottlieb and Oren, 1998; Ko and Prives, 1996). Analyses of a large number of mutant p53 genes in human tumors have revealed a strong selection for mutations that inactivate the specific DNA binding function of p53; most mutations in tumors are point mutations clustered in the core domain of p53 (residues 94-292) that harbours the specific DNA binding activity (Bérout and Soussi, 1998).

Both p53-induced cell cycle arrest and apoptosis could be involved in p53-mediated tumor suppression. While p53-induced cell cycle arrest could conceivably be reversed in different ways, p53-induced cell death would have advantage of being irreversible. There is indeed evidence from animal in vivo models (Symonds *et al.*, 1994) and human tumors (Bardeesy *et al.*, 1995) indicating that p53-dependent apoptosis plays a major role in the elimination of emerging tumors, particularly in response to oncogenic signaling. Moreover, the ability of p53 to induce apoptosis often determines the efficacy of cancer therapy (Lowe *et al.*, 1994). Taking into account the fact that more than 50% of human tumors carry p53 mutations, it appears highly desirable to restore the function of wild type p53-mediated growth suppression to tumors. The advantage of this approach is that it will allow selective elimination of tumor cells, carrying mutant p53. Tumor cells are particularly

sensitive to p53 reactivation, supposedly for two main reasons. First, tumor cells are sensitized to apoptosis due to oncogene activation (reviewed in (Evan and Littlewood, 1998)). Second, mutant p53 proteins tend to accumulate at high levels in tumor cells. Therefore, restoration of the wild type function to the abundant and presumably “activated” mutant p53 should trigger a massive apoptotic response in already sensitized tumor cells, whereas normal cells that express low or undetectable levels of p53 should not be affected. The feasibility of p53 reactivation as an anticancer strategy is supported by the fact that a wide range of mutant p53 proteins are susceptible to reactivation. A therapeutic strategy based on rescuing p53-induced apoptosis should therefore be both powerful and widely applicable.

It may be shown that malfunctioning of the p53 pathway is generally involved in a number of diseases, such as those enumerated herein above. Indeed, in addition to hyperproliferative diseases, such as cancer, various authors have shown the involvement of deficient p53 functioning in a number of other disease states, e.g. autoimmune diseases and cardiac diseases.

Thus, in an article by Mountz *et al.* (1994) it is stated that human autoimmune diseases share the common feature of an imbalance between the production and destruction of various cell types including lymphocytes (SLE), synovial cells (RA), and fibroblasts (scleroderma). Oncogenes, including bcl-2, p53, and myc, that regulate apoptosis are also expressed abnormally. According to the authors, specific therapies that induce apoptosis without incurring side effects should improve treatment of autoimmune disease.

Bonafe M *et al.* (2004) present data suggesting that p53 codon 72 polymorphism contributes to a genetically determined variability in apoptotic susceptibility among old people, which has a potentially relevant role in the context of an age-related pathologic condition, such as myocardial ischaemia.

Okuda *et al.* (2003) present results suggesting that p53 may be involved in the regulatory process of experimental autoimmune encephalomyelitis (EAE) through the control of cytokine production and/or the apoptotic elimination of inflammatory cells. EAE as a model for autoimmune inflammatory diseases of the central nervous system (CNS) is a widely used model for the human disease multiple sclerosis.

Taken together, these findings suggest that pharmacological restoration of p53 function would be beneficial in a number of disorders and diseases.

The present inventors have found that the compound PRIMA-1 (i.e. 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one) (disclosed in WO 02/24692), is able to induce apoptosis of cells carrying mutant p53. Later they also found some analogues to Prima-1 that showed similar results (disclosed in WO 03/070250). Nonetheless, there still remains a general need of compounds having activity in the treatment of disorders and diseases related to p53 malfunctioning. Preferably, such compounds should have improved pharmacokinetic and pharmacodynamic properties. One main objective of the present invention is to provide such compounds.

The present inventors surprisingly have found several azabicyclooctan-3-one derivatives showing high activity in the treatment of disorders and diseases related to p53 malfunctioning. They not only show high potency, but they are also believed to have very favourable ADME properties due to their higher cLogP value which will allow a high cellular uptake. Several of the analogs could also be considered as prodrugs to Prima-1.


The azabicyclooctan-3-one derivatives of the invention are considered potentially useful in the treatment of hyperproliferative diseases, autoimmune diseases and heart diseases and especially in the treatment of disorders wherein malfunctioning of the p53 pathway may be involved, and this discovery forms the basis of the present invention. Furthermore, the compounds in the present invention are believed to have additional effects that are positive for the treatment of the above mentioned disorders, such as will be further discussed herein below.

2-Substituted 3-quinuclidinones have been described earlier in biological context but not in the above-mentioned therapeutic areas. Thus, 2-[N'-(O-alkoxyphenyl)piperazinomethyl]-3-quinuclidinones (Biel *et al.* US patent no. 3,598,825) have been described as nervous system depressants and amine-substituted 2-methylene 3-quinuclidinones have been described as anti-bacterial agents (Elkin *et al.* US patent no. 3,726,877) and antidepressant agents (Biel *et al.* US patent no. 3,462,442).

Biel *et al.*, in US patent no. 3,384,641, describe a method wherein 2-methylene-3-quinuclidinone is reacted with amines to form intermediates which upon heating could release the amines. The intermediates thus are used for purification of amines.

Summary of the invention

According to one aspect, the present invention relates to the use of a compound of formula (I)



(I)

wherein

(i) R¹ and R² are the same or different and are selected from H, -CH₂-O-R⁵, -CH₂-O-SO₂-R⁵, -CH₂-S-R⁵, -CH₂-NR⁴R⁵, -CH₂-O-CO-R⁵, -CH₂-O-CO-NR⁴R⁵ and -CH₂-O-CO-OR⁵;

R³ is =O, =S or =NR⁵;

R⁴ and R⁵ are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; substituted or non-substituted benzyl; substituted or non-substituted mono- or bicyclic aryl; substituted or non-substituted mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or R⁴ and R⁵ in -CH₂-NR⁴R⁵ are bonded together and form, together with the nitrogen atom to which they are bonded, a substituted or non-substituted non-aromatic C1-C10 mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups; with the proviso that when R¹ and R² are both -CH₂-OR⁵ then R⁵ is not H; and with the further proviso that when one of R¹ and R² is H and the other one is -CH₂-NR⁴R⁵, then R⁴ and R⁵ are not substituted or non-substituted monocyclic aryl; or

(ii) R¹ and R² together with the carbon atom to which they are bonded form an substituted or non-substituted cyclic carbonate;

wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C1-C10 heteroaryl and non-aromatic C1-C10 heterocyclyl wherein the

heteroatoms are independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR⁶; CONR⁶R⁷; and COOR⁶;

R⁶ and R⁷ are the same or different and are selected from H;

unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl;

benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10


heterocyclyl wherein the heteroatoms are independently selected from N, O and S; as well as

of pharmaceutically acceptable salts or prodrugs thereof, for preparing a medicament for the treatment of a disorder selected from hyperproliferative diseases, autoimmune diseases, and heart diseases.

According to a further aspect, the present invention provides the use of the compounds of formula (I) or pharmaceutically acceptable salts or prodrugs thereof for the treatment of diseases associated with mutant p53 or, more generally, a malfunctioning p53 signalling pathway.

According to another aspect, the invention provides a method of treatment of a disease selected from hyperproliferative diseases, autoimmune diseases, and heart diseases by administration of a therapeutically effective amount of a compound of formula (I) to a mammal in need of such treatment.

According to a further aspect, the invention relates to a compound of formula (I)



(I)

wherein

(i) R¹ and R² are the same or different and are selected from H, -CH₂-O-CO-R⁵, -CH₂-O-CO-NR⁴R⁵ and -CH₂-O-CO-OR⁵;

R³ is =O, =S or =NR⁵;

R⁴ and R⁵ are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; substituted or non-substituted benzyl; substituted or non-substituted mono- or bicyclic aryl;


substituted or non-substituted mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or R⁴ and R⁵ in -CH₂-NR⁴R⁵ are bonded together and form, together with the nitrogen atom to which they are bonded, a substituted or non-substituted non-aromatic C1-C10 mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups; with the proviso that R¹ and R² are not both H; or

(ii) R¹ and R² together with the carbon atom to which they are bonded form a substituted or non-substituted cyclic carbonate;

wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR⁶; CONR⁶R⁷; and COOR⁶;

R⁶ and R⁷ are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; as well as pharmaceutically acceptable salts or prodrugs of the compounds of formula (I).

According to another aspect, the present invention provides methods of preparing said compounds by reacting a compound of formula (I)



(I)

wherein R¹, R² and R³ are as defined herein above, provided that at least one of R¹ and R² is -CH₂OH; or wherein both R¹ and R² are -CH₂OH and R³ is as defined herein above; under conditions suitable for transforming at least one of R¹ and R² into -CH₂-O-CO-R⁵, -CH₂-O-CO-NR⁴R⁵ or -CH₂-O-CO-OR⁵ wherein R⁴ and R⁵ are as defined herein above.

According to a still further aspect, the invention provides new pharmaceutical compositions comprising said compounds, or salts or prodrugs thereof.

Any further aspects are as defined in the claims.

Brief description of the drawings

The Figures 1-11 represent results from FACS analysis of a selected number of compounds.

Detailed description of the invention

As used herein the term "lower alkyl" unless otherwise stated, means an unbranched or branched, cyclic, saturated or unsaturated (alkenyl or alkynyl) hydrocarbyl radical. Where cyclic, the alkyl group is preferably C3 to C12, more preferably C5 to C10, most preferably C5-C7. Where acyclic, the alkyl group is preferably C1 to C10, more preferably C1 to C6, more preferably methyl, ethyl, propyl (n-propyl, isopropyl), butyl (branched or unbranched) or pentyl, most preferably methyl.

As used herein, the term "aryl" means an aromatic group, such as phenyl or naphthyl.

As used herein, the term "functional groups" means in the case of unprotected: hydroxy-, thio-, aminofunction, carboxylic acid and in the case of protected: lower alkoxy, N-, O-, S-acetyl, carboxylic acid ester.

As used herein, the term "heteroaryl" means a mono-, bi-, or tricyclic heteroaromatic group containing one or more heteroatom(s) preferably selected from N, O and S, such as pyridyl, pyrrolyl, quinoliny, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrimidinyl, indolyl, pyrazinyl, indazolyl, pyrimidinyl, thiophenetyl, pyranyl, carbazolyl, acridinyl, quinoliny, benzimidazolyl, benzthiazolyl, purinyl, cinnoliny and pteridinyl.

As used herein, the term "non-aromatic heterocycle" means a non-aromatic cyclic group containing one or more heteroatom(s) preferably selected from N, O and S, such as a pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, tetrahydrofuranyl or monosaccharide.

As used herein the term "halogen" means a fluorine, chlorine, bromine or iodine.

As used herein, and unless specified otherwise, the term "substituted" means that the concerned groups are substituted with at least one functional group, such as hydroxyl, amine, sulfide, silyl, carboxylic acid, halogen, aryl, etc.

The compounds according to formula (I) will be useful for treating various diseases such as hyperproliferative diseases, e.g. cancer, autoimmune diseases, such as rheumatoid arthritis and Sjogren's syndrome, and heart diseases such as hereditary idiopathic cardiomyopathy. The treatment may be preventive, palliative or curative.

Examples of pharmaceutically acceptable addition salts for use in the pharmaceutical compositions of the present invention include those derived from mineral acids, such as hydrochlorid, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, and arylsulphonic acids. The pharmaceutically acceptable excipients described herein, for example, vehicles, adjuvants, carriers or diluents, are well-known to those who are skilled in the art and are readily available to the public. The pharmaceutically acceptable carrier may be one that is chemically inert to the active compounds and that has no detrimental side effects or toxicity under the conditions of use. Pharmaceutical formulations are found e.g. in Remington: The Science and Practice of Pharmacy, 19th ed., Mack Printing Company, Easton, Pennsylvania (1995).


Prodrugs of the compounds of formula (I) may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, in vivo when such prodrug is administered to a mammalian subject. The modifications typically are achieved by synthesizing the parent compound with a prodrug substituent. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, sulfhydryl, carboxy or carbonyl group in a compound of formula (I) is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, esters groups of carboxyl functional groups, N-acyl derivatives, N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. "Design of Prodrugs" p1-92, Elsevier, New York-Oxford (1985).

The composition according to the invention may be prepared for any route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, or intraperitoneal. The precise nature of the carrier or other material will depend on the route of administration. For a parenteral administration, a parenterally acceptable aqueous solution is employed, which is pyrogen free and has requisite pH, isotonicity and stability. Those skilled in the art are well able to prepare suitable solutions and numerous methods are described in the literature. A brief review of methods of drug delivery is also found in e.g. Langer, Science 249:1527-1533 (1990).

The dose administered to a mammal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the mammal over a reasonable time frame. One skilled in the art will recognize that dosage will depend upon a variety of factors including the potency of the specific compound, the age, condition and body weight of the patient, as well as the stage/severity of the disease. The dose will also be determined by the route (administration form) timing and frequency of administration. In the case of oral administration the dosage can vary from about 0.01 mg to about 1000 mg per day of a compound of formula (I) or the corresponding amount of a pharmaceutically acceptable salt thereof.

The compounds of the present invention may be used or administered in combination with one or more additional drugs useful in the treatment of hyperproliferative diseases. The components may be in the same formulation or in separate formulations for administration simultaneously or sequentially. The compounds of the present invention may also be used or administered in combination with other treatment such as irradiation for the treatment of cancer.


In their study of the inventive compounds, the present inventors found a common metabolite of many of the inventive compounds namely methylene quinuclidinone. The inventors have shown that this metabolite is able to form conjugates with glutathione (GSH) (Reaction Scheme 1).



Reaction Scheme 1

While not wishing to be bound by any theory, the inventors believe that compounds of the present invention may synergistically enhance the effect of a further pharmaceutically active compounds that in vivo are metabolized by a pathway comprising reaction with glutathione. The explanation would be that the inventive compounds, by reducing the amount of intracellular glutathione, increase the potency of the further pharmaceutically active compound. Examples of such further pharmaceutically active compounds are adriamycin, melphalan, cisplatin.

As stated herein above, according to one aspect of the invention, methods of preparing the compounds according to formula (I) are provided. Examples of synthesis of some compounds according to formula (I) are represented in the following Reaction Scheme 2:



Reaction Scheme 2

According to the Reaction Scheme 2, quinuclidinone hydrochloride (1) is used as the starting material for the synthesis of the intermediates (2), (7) and (8). 2,2-Bis-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (2) is formed by treatment of (1) with an excess of formaldehyde and potassium carbonate according to methods described by Nielsen *et al.* (1966). 2-Hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (7) is formed by treatment of quinuclidinone hydrochloride with 1 equiv. of formaldehyde and potassium carbonate. 2-Methylene-1-aza-bicyclo[2.2.2]octan-3-one (8) is formed from compound 7 by a dehydration procedure. These methods are also described by Nielsen *et al.* (1966). Compound 8 is also commercially available as its hydrochloride salt.

2,2-Bis-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (**2**) forms esters by treatment with acid chlorides and a suitable base such as triethylamine, pyridine or DMAP in an organic solvent following standard protocols for acylation. The esterification may also be performed using carboxylic acids and coupling reagents such as DCC and HOBT. Carbonates and carbamates can also be formed by methods well known for the person skilled in the art. By using only 1 equiv. of the reagent the monocoupled derivatives are obtainable. The monoacylated derivative and the corresponding monocarbonate and monocarbamate may be separated from the disubstituted derivatives by liquid chromatography.

Compound **15** and analogs thereof may be formed by reaction between 2-methylene-1-aza-bicyclo[2.2.2]octan-3-one (**8**) and amines in organic solvents and at elevated temperature in the same way as described by Singh *et al.* (1969) or by Elkin *et al.* (US patent no.3726877).

Compound **6** and analogs thereof may be formed from 2,2-bis-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (**2**) by alkylation, either with alkylhalides using a method as described by Schieweck *et al.* (2001) or by the use of orthoester as described by Sampath Kumar *et al.* (1997).

Compound **10** can also be formed either from compound **8** or from compound **1** by a method as described by Toender *et al.* (2000).

Compound **14** may be formed either by reacting compound **8** with alcohols under basic conditions as described by Nielsen *et al.* (1966) or by alkylation of compound **7** with alkyl halides according to Schieweck *et al.* (2001).

The synthesis of compounds **11**, **12**, **13** from compound **7** may be performed by methods well known to the person skilled in the art.

Examples

Example 1. Synthesis of 2,2-Bis-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (**2**) (intermediary)


The reaction of quinuclidinone hydrochloride (**1**) (commercially available) (16.9 g, 0.1 mol) with formalin (37%w/w, 150 mL, 2.0 mol) in the presence of potassium carbonate (15.9 g, 0.11 mol) consumed the starting material after 1h at 52 °C. Conversion was followed by LC-

MS. The water based reaction mixture was extracted with methylene chloride (4x80 mL) and the combined organic phases were dried over MgSO₄. The solvent was evaporated off and heptane (500 mL) was added to the residue. After heating for one hour the hot heptane extract was discharged. Benzene (400mL) was added to the residue followed by heating for 8 hours. The resulting mixture was clear filtered from polymer that formed during the heating, and the clear solution was evaporated to dryness. The residue was extracted with boiling heptane (300 mL).

After decanting the heptane, boiling benzene (400 mL) was added to the residue. Clear filtration and cooling (to 6°C) followed by isolation by filtration of the solid precipitate yielded 5.1 g of 2,2-bis-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (**2**) (mp: 136-138 °C). A second crop was isolated from combined mother liquor and material from heptane extraction after precipitation in benzene yielding 2.9 g of the product. In total 37% yield.


Example 2. Methods for O-acylation of 2,2-bis-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (**2**)

2.1 Isobutyric acid 2-isobutyryloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-ylmethyl ester




To a stirred solution of bismethylol of 3-quinuclidinone (0.25g, 1.35 mmol) in dry dichloromethane (15 ml), 4-dimethylamino pyridine (33 mg, 0.27 mmol) and triethylamine (0.75g, 7.4 mmol) were added under nitrogen atmosphere. The reaction mixture was cooled to 0°C, isobutyryl chloride (0.31g, 0.9 mmol) was added slowly at 0°C and stirring was continued for 18-20h at room temperature (26-27°C). The reaction mixture was quenched with cold water (25 ml), extracted with dichloromethane (3X50 ml), the organic layers were washed with 10% NaHCO₃ solution, brine and dried over sodium sulphate, filtered and concentrated to get the crude product. The crude product was purified as a viscous liquid (225mg, 52%) by column chromatography on silica gel using 0.8: 99.2 methanol : chloroform as eluent.

2.2 Acetic acid 2-acetoxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethyl ester




To a stirred solution of bismethylol of 3-quinuclidinone (0.25g, 1.35 mmol) in dry dichloromethane (15 ml), 4-dimethylamino pyridine (33 mg, 0.27 mmol) and triethylamine (0.75g, 7.4 mmol) were added under nitrogen atmosphere. The reaction mixture was cooled to 0°C, acetyl chloride (0.23g, 2.9 mmol) was added slowly at 0°C and stirring was continued for 18h at room temperature (26-27°C). The reaction mixture was quenched with cold water (25 ml), extracted with dichloromethane (3X50 ml), the organic layers were washed with 10% NaHCO₃ solution, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified as a yellow liquid (100mg, 27%) by column chromatography on silica gel using 1: 99 methanol : chloroform as eluent.

2.3 Dicyclobutanecarboxylic acid 3-oxo-1-aza-bicyclo[2.2.2]oct-yl-2,2 dimethyl ester




To a stirred solution of bismethylol of 3-quinuclidinone (0.25g, 1.35 mmol) in dry dichloromethane (15ml), 4-dimethylamino pyridine (0.41g, 3.3 mmol) was added under nitrogen atmosphere. The reaction mixture was cooled to 0°C, cyclobutane carbonyl chloride (0.35g, 2.9 mmol) was added slowly at 0°C and stirring was continued for 18h at room temperature (26-27°C). The reaction mixture was quenched with cold water (25 ml), extracted with dichloromethane (3X50ml), the organic layers were washed with 10% NaHCO₃ solution, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified as a yellow liquid (200mg, 42.5%) by column chromatography on silica gel using 1: 99 methanol : chloroform as eluent.

2.4 Dibenzoic acid 3-oxo-1-aza-bicyclo[2.2.2]oct-yl-2,2 dimethyl ester




To a stirred solution of bismethylol of 3-quinuclidinone (0.25g, 1.35 mmol) in dry dichloromethane (15 ml), 4-dimethylamino pyridine (33 mg, 0.27 mmol) and triethylamine (0.75g, 7.4 mmol) were added under nitrogen atmosphere. The reaction mixture was cooled to 0°C, benzoyl chloride (0.41g, 2.9 mmol) was added slowly at 0°C and stirring was continued for 18h at room temperature (26-27°C). The reaction mixture was quenched with cold water (25 ml), extracted with dichloromethane (3X50ml), the organic layers were washed with 10% NaHCO₃ solution, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified as off white solids (130mg, 25%) by column chromatography on silica gel using 1: 99 methanol : chloroform as eluent.

2.5 Butyric acid 2-butyryloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethyl ester




To a stirred solution of bismethylol of 3-quinuclidinone (0.25g, 1.35 mmol) in dry dichloromethane (25 ml), 4-dimethylamino pyridine (33mg, 0.27 mmol) and triethylamine (0.75g, 7.4 mmol) were added under nitrogen atmosphere. The reaction mixture was cooled to -5°C, butyryl chloride (0.31ml, 2.9 mmol) was added slowly at 0°C and stirring was continued for 18h at room temperature (26-27°C). The reaction mixture was quenched with cold water (25 ml), extracted with dichloromethane (3X50ml), the organic layers were washed with 10% NaHCO₃ solution, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (316mg, 71%) by column chromatography on silica gel using 1: 99 methanol : chloroform as eluent.

2.6 Dicyclopentanecarboxylic acid 3-oxo-1-aza-bicyclo[2.2.2]oct-yl-2,2 dimethyl ester



To a stirred solution of bismethylol of 3-quinuclidinone (0.25g, 1.35 mmol) in dry dichloromethane (15 ml), 4-dimethylamino pyridine (33 mg, 0.27 mmol) and triethylamine (0.75g, 0.0074 mol) were added under nitrogen atmosphere. The reaction mixture was cooled to 0°C, cyclopentane carbonyl chloride (0.39g, 0.0029 mol) was added slowly at 0°C and stirring was continued for 18h at room temperature (26-27°C). The reaction mixture was quenched with cold water (25 ml), extracted with dichloromethane (3X50 ml), the organic layers were washed with 10% NaHCO₃ solution, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified as off white solids (130mg, 25%) by column chromatography on silica gel using 1: 99 methanol : chloroform as eluent.


2.7 (2-Methoxy-ethoxy)-acetic acid 2-[2-(2-methoxy-ethoxy)-acetoxymethyl]-3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethylester



To a stirred solution of bismethylol of 3-quinuclidinone (0.25g, 1.35 mmol) in dry dichloromethane (20 ml) triethylamine (0.75ml) and 4-dimethylamino pyridine (33mg) was added very slowly at -15°C under nitrogen atmosphere. The reaction mixture was allowed to warm up to 0°C and 2-(2-methoxy ethoxy) acetyl chloride (450mg, 2.9 mmol) was added slowly to the reaction mixture at the same temperature under nitrogen and allowed to stir at that temperature for 1h. Then the reaction mixture was allowed to warm up to RT and stirring was continued for overnight at RT. The completion of reaction was monitored by tlc. The reaction mixture was quenched with ice (50g), extracted with dichloromethane (3X20 ml), organic layers were washed with 10% NaHCO₃ solution, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (100mg, 20 %) by column chromatography on neutral silica gel using 99.8 : 0.2 chloroform : methanol as eluent.

Example 3. Methods for O-tosylation of 2,2-bis-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (2)


3.1 Benzenesulfonic acid 2-hydroxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethyl ester



To a stirred solution of bismethylol of 3-quinuclidinone (1g, 5.4 mmol) in dry dichloromethane (20 ml) triethylamine (1.63g) was added very slowly at RT under nitrogen atmosphere. The reaction mixture was cooled to -20°C and a solution of tosyl chloride (2.7 mmol) in dry dichloromethane (20 ml) was added slowly to the reaction mixture at the same temperature and allowed to stir at that temperature for 1h. Then the reaction mixture was allowed to warm up to RT and stirring was continued for 48h at RT. The reaction mixture was quenched with ice-cold water (50 ml), extracted with dichloromethane (3X50 ml), the organic layers were washed with brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (200mg, 11%) by column chromatography on silica gel using chloroform as eluent.

Example 4. Methods for O-carboxylation of 2,2-bis-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (2)


4.1 Carbonic acid 2-methoxycarbonyloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethyl ester methyl ester



To a stirred solution of bismethylol of 3-quinuclidinone (0.5g, 2.6 mmol) in dry dichloromethane (25ml) pyridine (1.3 ml) was added very slowly at RT under nitrogen atmosphere. The reaction mixture was cooled to -5°C and methyl chloroformate (0.5ml) was added slowly to the reaction mixture at the same temperature under nitrogen and allowed to stir at that temperature for 0.5h. Then the reaction mixture was allowed to warm up to RT and stirring was continued for 14h at RT. The reaction mixture was quenched with ice-cold water (30 ml), extracted with dichloromethane (3X25 ml), organic layers were washed with brine and dried


over sodium sulphate, filtered and concentrated to get the crude product which was purified (170mg, 21 %) by column chromatography on neutral silica gel using 98:2 chloroform : methanol as eluent.

4.2 Carbonic acid 2-isobutoxycarbonyloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethyl ester isobutyl ester



To a stirred solution of 2,2-bis-hydroxymethyl quinuclidinone (0.5g, 2.6 mmol) in dry dichloromethane (25ml) pyridine (1.28g, 16.1 mmol) was added slowly at RT under nitrogen atmosphere and the reaction mixture was then cooled to 5°C. Isobutylchloroformate (0.92g, 6.7 mmol) was added slowly to the reaction mixture at the same temperature under nitrogen and the reaction mixture was stirred for 0.5h at the same temperature. Then the reaction mixture was allowed to warm up to RT and stirring was continued for 19h at RT. The reaction mixture was quenched with ice-cold water (50ml), extracted with dichloromethane (3X50 ml), washed with water, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (550mg, 55%) by column chromatography on silica gel using 0.5 : 99.5 methanol : chloroform as eluent.

4.3 Spiro-2,2-([1,3]-dioxan-2-one)-azabicyclo[2.2.2]octan-3-one




To a stirred solution of solketal (2.8g, 0.02mol) in dry dichloromethane (150ml) pyridine (5g, 0.0635mol) was added slowly at RT under nitrogen atmosphere and the reaction mixture was then cooled to 5°C. Then a 20% solution of phosgene in toluene (15.7ml) was added very slowly at the same temperature and stirred for 0.5h. The reaction mixture was warmed up to RT and stirred at RT for 3h. Again the reaction mixture was allowed to cool to 0°C and 2,2-bis-(hydroxymethyl) quinuclidinone (1g, 5.4 mmol) in dry dichloromethane (25ml) was added to the reaction mixture and the reaction mixture was then warmed up to RT and stirred for 17h

at RT. The reaction mixture was quenched with ice-cold water (100ml) and stirred for 0.5h, extracted with dichloromethane (3X100 ml), washed with water, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (500mg, 11%) by column chromatography on silica gel using 1 : 99 methanol : chloroform as eluent.


Example 5. Method for amination of 2-methylene-1-aza-bicyclo[2.2.2]octan-3-one (8)

5.1 5-Fluoro-1-(3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethyl)-1H-pyrimidine-2,4-dione




To a stirred solution of 2-methylene-3-quinuclidinone (500mg, 3.65 mmol) in dry DMF (10ml) 5-fluorouracil (470mg, 3.6 mmol) was added at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 14h. Completion of reaction was monitored by tlc. The reaction mixture was poured over crushed ice. The off-white solids that appeared were filtered and washed with hexane. The solids were then taken in chloroform and stirred for 12h, filtered and dried to get pure product (150mg).

5.2 2-(2,3-Dihydro-indol-1-ylmethyl)-1-aza-bicyclo[2.2.2]octan-3-one




To a stirred solution of 2-methylene-3-quinuclidinone (0.5g, 0.0028 mol) in water (6ml) indoline (0.66g, 0.0057 mol), triethylamine (0.84g, 0.0084 mol) and tetra-n-butyl ammonium bromide (90mg, 0.00028 mol) were added and the reaction mixture were allowed to stir at 80°C for 18-20h. The reaction mixture was quenched with ice-cold water (20 ml), extracted with dichloromethane (3X50 ml), the organic layers were washed with brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified as greenish yellow solids (125mg, 17%) by column chromatography on neutral silica gel using chloroform as eluent.

5.3 2-[(Ethyl-pyridin-4-ylmethyl-amino)-methyl]-1-aza-bicyclo[2.2.2]octan-3-one




To a stirred solution of 2-methylene-3-quinuclidinone hydrochloride (0.5g, 0.0036mol) in water (3ml) N-(4-pyridylmethyl)ethylamine (0.49g, 0.0036mol), triethylamine (1.09g, 0.0108mol) and tetra-n-butyl ammonium bromide (116mg, 0.00036mol) were added and the reaction mixture were allowed to stir at 80°C for 18h. The completion of reaction was monitored by tlc. The reaction mixture was quenched with ice-cold water (10 ml), extracted with dichloromethane (2X50 ml), organic layers were washed with 10% NaHCO₃ solution, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified as yellow solids (200mg, 22%) by flash column chromatography on neutral silica gel using chloroform as eluent.


5.4 2-[4-(Furan-2-carbonyl)-piperazin-1-ylmethyl]-1-aza-bicyclo[2.2.2]octan-3-one



To a stirred solution of 2-methylene-3-quinuclidinone hydrochloride (0.5g, 0.0036mol) in water (3ml) 1-(2-furoyl)piperazine (0.64g, 0.0036mol), triethylamine (1.09g, 0.0108mol) and tetra-n-butyl ammonium bromide (116mg, 0.00036mol) were added and the reaction mixture was allowed to stir at 80°C for 20h. The completion of reaction was monitored by tlc. The reaction mixture was quenched with ice-cold water (10 ml), extracted with dichloromethane (2X50 ml), the organic layers were washed with 10% NaHCO₃ solution, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified as yellow solids (100mg, 9%) by flash column chromatography on neutral silica gel using chloroform as eluent.

5.5 2-(3,5-Dimethyl-piperidin-1-ylmethyl)-1-aza-bicyclo[2.2.2]octan-3-one


To a stirred solution of 2-methylene-3-quinuclidinone hydrochloride (0.25g, 0.0014mol) in water (5ml) 3,5-dimethylpiperidine (0.32g, 0.0028mol), triethylamine (0.84g, 0.0084mol) and tetra-n-butyl ammonium bromide (45mg, 0.00014mol) were added and the reaction mixture were allowed to stir at 80°C for 18h. The completion of reaction was monitored by tlc. The reaction mixture was quenched with ice-cold water (20ml), extracted with dichloromethane (3X50 ml), the organic layers were washed with brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (100mg) by flash column chromatography on neutral silica gel using chloroform as eluent.

Example 6. Method for alkoxylation (or aroxylation) of 2-methylene-1-aza-bicyclo[2.2.2]octan-3-one (8)**6.1 2-Propoxymethyl-1-aza-bicyclo[2.2.2]octan-3-one**

To a stirred solution of 2-methylene-3-quinuclidinone (100mg) in dry dichloromethane (5ml) propanol (1 equiv., 0.04ml) was added in presence of molecular sieves (4Å). The reaction mixture was stirred at RT for overnight. The reaction mixture was filtered and the filtrate was concentrate to get crude product, which was purified (70mg, 50%) by column chromatography on silica gel using 0.5% methanol in chloroform as eluent.


Example 7. Method for formation of thioethers of 2-methylene-1-aza-bicyclo[2.2.2]octan-3-one (8)

7.1 2-(9H-Purin-6-ylsulfanylmethyl)-1-aza-bicyclo[2.2.2]octan-3-one



To a stirred solution of 2-methylene-3-quinuclidinone hydrochloride (0.5g, 3.6 mmol) in water (6ml) triethylamine (1.5ml), tetra-n-butyl ammonium bromide (120mg) and 6-mercaptapurine monohydrate (0.62g) were added and the reaction mixture was allowed to stir at 85°C for 14h. The completion of reaction was monitored by tlc. The reaction mixture was quenched with ice-cold water (10 ml), extracted with dichloromethane (2X25ml), the organic layers were washed with water, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (140mg, 14%) by flash column chromatography on neutral silica gel using 9:1 chloroform:methanol as eluent.


7.2 (RS)-2-Phenylsulfanylmethyl-1-aza-bicyclo[2.2.2]octan-3-one



To a stirred solution of 2-methylene-3-quinuclidinone hydrochloride (1g, 0.0057mol) in water (10ml) triethylamine (1.73g, 0.0171mol), tetra-n-butyl ammonium bromide (180mg, 0.0057mol) and thiophenol (0.63g, 0.0057mol) were added and the reaction mixture was allowed to stir at 80°C for 18h. The completion of reaction was monitored by tlc. The reaction mixture was quenched with ice-cold water (20 ml), extracted with dichloromethane (4X50 ml), organic layers were washed with brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (550mg) by column chromatography on silica gel using chloroform as eluent.

Example 8. Method for formation of carbamates of 2,2-bis-hydroxymethyl-1-aza-bicyclo[2.2.2]octan-3-one (2)


8.1 Pyrrolidine-carbamic acid 2-[(Pyrrolidine -carbamoxyloxy)-methyl]-3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethyl ester



To a stirred solution of bismethylol of 3-quinuclidinone (1g, 0.0054mol) in dry THF (40ml) pyridine (0.93g, 0.0118mol) was added under nitrogen atmosphere. The reaction mixture was cooled to 5°C. A solution of 4-nitrophenylchloroformate (2.2g, 0.0113mol) in dry THF (10ml) was added slowly at 5°C and stirring was continued for 18h at room temperature (26-27°C). The reaction mixture was quenched with 10% aqueous NaHCO₃ solution (100ml), extracted with dichloromethane (3X100 ml), the organic layers were washed with brine and dried over sodium sulphate, filtered and concentrated to get the crude product, which was purified as yellow solids intermediate A (400mg, 15%) by column chromatography on silica gel using chloroform as eluent.

To a stirred solution of pyrrolidine (28mg, 0.0004 mol) in pyridine (5ml) the intermediate A (100mg, 0.00019mol) was added at -5°C under nitrogen atmosphere. The reaction mixture was allowed to stir at RT for 15h. Excess pyridine was removed under vacuum. The reaction mixture was then quenched with ice-water (20ml), extracted with dichloromethane (3X50 ml), dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (40mg, 57%) by column chromatography on silica gel using 0.1% methanol in chloroform as eluent.


8.2 Bis-(2-chloro-ethyl)-carbamic acid 2-[[bis-(2-chloro-ethyl)-carbamoyloxy]-methyl]-3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethyl ester



To a stirred solution of bismethylol of 3-quinuclidinone (2g, 0.0108mol) in dry THF (100ml) pyridine (1.8ml, 0.0236mol) was added under nitrogen atmosphere. The reaction mixture was cooled to -5°C . A solution of 4-nitrophenylchloroformate (4.4g, 0.0226mol) in dry THF (50ml) was added slowly at -5°C and stirring was continued for 12h at room temperature ($26-27^{\circ}\text{C}$). The reaction mixture was quenched with 10% aqueous NaHCO_3 solution (100ml) and extracted with dichloromethane (3X100 ml). The organic layers were washed with water, brine and dried over sodium sulphate, filtered and concentrated to get the crude product, which was purified by recrystallisation to get pure intermediate A (560mg, 10%).

To a stirred solution of bis (2-chloroethyl) amine hydrochloride (430mg) in pyridine (20ml) the intermediate A (400mg) was added at 0°C under nitrogen atmosphere. The reaction mixture was allowed to stir at RT for 10h. Excess pyridine was removed under vacuum, then quenched with ice-water (20ml), extracted with dichloromethane (3X25ml), organic layers were washed with brine, dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (190mg, 47%) by column chromatography on silica gel using 1% methanol in chloroform as eluent.

8.3 Dimethyl-carbamic acid 2-dimethylcarbamoyloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-2-ylmethyl ester



To a stirred solution of bismethylol of 3-quinuclidinone (1g, 0.0054mol) in dry dichloromethane (50ml) pyridine (2.5g, 0.0318mol) was added and the reaction mixture was cooled to

5°C. N,N-dimethyl carbonyl chloride (1.45g, 0.0134mol) was added slowly at 5°C under nitrogen and stirring was continued for another 30 minutes. The reaction mixture was warmed up to RT and stirred for 19h. The reaction mixture was quenched with ice-cold water (50ml), extracted with dichloromethane (3X50ml), washed with water, brine and dried over sodium sulphate, filtered and concentrated to get the crude product which was purified (125mg) by column chromatography on silica gel using 0.5 : 99.5 methanol : chloroform as eluent.

Biology tests

The human H1299-His175 lung carcinoma cell line that carries a tetracycline-regulated mutant p53 construct was used for studying the antiproliferative and apoptosis inducing effects of the present compounds.

WST-1 assay protocol

Cell Culture

Cells were cultured in Iscove's Modified Dulbecco's Medium supplemented with 10% fetal bovine serum, L-glutamine and gentamycin.

Seeding of cells

Cells were taken out for experiment when they were at about 75-100% confluent. After trypsinization, cells were diluted to a cell concentration of 30 000 cells/ml in cell culture medium. Cells were placed in 96-wells plates with flat bottom at 100 µl/well (3000 cells/well). The last column of the plate was filled with medium alone, 100 µl/well, to use as blank. Cells were then incubated over night in the cell incubator.

Treatment of cells

After about 16-24 hours of incubation in 96-wells plates, the cells were treated with the different compounds. The drugs were dissolved in DMSO at a concentration of 0.1 M and then further diluted to desired concentrations in PBS. 5 µl of each compound was then added to each well. One column of cells was usually left untreated as control. Cell plates were put back in the cell incubator.

Addition of WST-1 reagent

After 96 hours in the cell incubator, the WST-1 reagent was added to the plates. 10 µl of reagent was added to each well of the plates (including untreated cells and wells with medium







alone). The absorbance of the samples was measured in a spectrophotometer at 450 nm after about 1-2 hours of incubation in the cell incubator. Before reading the plates, they were checked visually by comparing the color in the wells with medium alone and the color in wells with untreated cells. The medium should remain red-pink in color whereas the untreated cells should switch from red-pink to orange.

Analysis of WST-1
















The average of the absorbance values for the untreated cells was calculated for each plate. The % of growth suppression was calculated as: $100 - ((\text{Abs}_{\text{sample}} / \text{Abs}_{\text{untreated cells}}) \times 100)$.

The results of WST-1 analyses are expressed as IC50 values, i.e. concentration that suppresses growth of at least 50% of the cells. The IC50 values of various compounds according to the invention, as well as of one reference compound not according to the invention, are shown in Table 1. In those cases where the compound according to the invention has been tested in the form of an acid addition salt the corresponding acid is shown in Table 1.
















Table 1 Examples of tested compounds and IC50 values from WST-1 assay

		
12.5 μM	19.3 μM	38 μM
		
20.0 μM	14.2 μM	14 μM


Cont. Table 1

		
18 μM	25 μM	20 μM
		
13.51 μM	40 μM	18 μM
		
>50 μM	33 μM	15 μM
		
20 μM	35 μM	>>50 μM^a
		
17 μM	40 μM	8.5 μM


Cont. Table 1

14.4 μM 50 μM 8.5 μM 33.0 μM 35 μM 3 μM 14.8 μM 25.2 μM 8.6 μM 17.5 μM 35 μM 4 μM 20 μM 6.3 μM 6.8 μM

Cont. Table 1



Cont. Table 1



^aCompound not according to the invention

FACS analysis


H1299-His175 cells were plated in 6-wells plates at the initial density of 10,000 cells/cm², cultured overnight and treated with compounds of the invention. After 24 hours of treatment, the medium containing floating cells was collected and pooled with harvested adherent cells. The cells were washed once in PBS and resuspended in 200 μl PBS. Ice-cold 70% ethanol was added while vortexing and the cells were stored at -20° C for 24 hours. Fixed cells were then collected by centrifugation, washed once in PBS and incubated in 100 μl PI staining buffer (5 $\mu\text{g}/\text{ml}$ PI and 250 $\mu\text{g}/\text{ml}$ RNaseA) for 30 minutes in 37°C. Samples were assayed using a FACSCalibur flow cytometer and the sub G₀/G₁ peak quantified using CELLQuest software. Results obtained with compounds according to the invention are shown in the Figure.

References

- Bardeesy *et al.*, *Cancer Res* **55**, 215-9 (1995).
- Bennett, M., *et al.* *Science* **282**, 290-293 (1998).
- Béroud, C. & Soussi, T., *Nucl. Acids Res.* **26**, 200–204 (1998).
- Biel *et al.* US patent no. 3,384,641
- Biel *et al.* US patent no. 3,462,442
- Biel *et al.* US patent no. 3,598,825
- Evan, G. & Littlewood, T., *Science*. **281**, 1317–1322 (1998).
- Elkin *et al.* US patent no. 3,726,877
- Gottlieb and Oren, *Semin Cancer Biol* **8**, 359-68 (1998),
- Ko, L.J. & Prives, C., *Genes Dev.* **10**, 1054–1072 (1996).
- Lowe *et al.*, 1994 *Science* **266**, 807-10 (1994).
- Morgan *et al.*, *J. Med. Chem.* **30**, 2559-2569 (1987).
- Nielsen *et al.*, *J. Org. Chem.* **31**, 1053-1057(1966).
- Sakamuri *et al.*, *Tetrahedron Lett.* **41**, 9949-9952 (2000).
- Sampath Kumar *et al.*, *Tetrahedron Lett.* **38**, 3619-3622 (1997).
- Schieweck *et al.*, *J. Chem. Soc., Perkin Trans. 1*, 3409-3414 (2001).
- Sherr, C.J., *Genes Dev.* **12**, 2984–2991 (1998).
- Singh *et al.*, *J. Med. Chem.* **12**, 524-526 (1969).
- Symonds *et al.*, *Cell* **78**, 703-711 (1994).
- Toender *et al.*, *Tetrahedron.* **56**, 1139-1146 (2000).
- WO 02/24692
- WO 03/070250

Claims

1. The use of a compound of formula (I)



(I)

wherein

(i) R¹ and R² are the same or different and are selected from H, -CH₂-O-R⁵, -CH₂-O-SO₂-R⁵, -CH₂-S-R⁵, -CH₂-NR⁴R⁵, -CH₂-O-CO-R⁵, -CH₂-O-CO-NR⁴R⁵ and -CH₂-O-CO-OR⁵;

R³ is =O, =S or =NR⁵;

R⁴ and R⁵ are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C₃-C₁₂ cycloalkyl or C₁-C₁₀ alkyl; substituted or non-substituted benzyl; substituted or non-substituted mono- or bicyclic aryl; substituted or non-substituted mono-, bi- or tricyclic C₁-C₁₀ heteroaryl or non-aromatic C₁-C₁₀ heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or R⁴ and R⁵ in -CH₂-NR⁴R⁵ are bonded together and form, together with the nitrogen atom to which they are bonded, a substituted or non-substituted non-aromatic C₁-C₁₀ mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups; with the proviso that when R¹ and R² are both -CH₂-OR⁵ then R⁵ is not H; and with the further proviso that when one of R¹ and R² is H and the other one is -CH₂-NR⁴R⁵, then R⁴ and R⁵ are not substituted or non-substituted monocyclic aryl; or

(ii) R¹ and R² together with the carbon atom to which they are bonded form an substituted or non-substituted cyclic carbonate;


wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C₃-C₁₂ cycloalkyl or C₁-C₁₀ alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C₁-C₁₀ heteroaryl and non-aromatic C₁-C₁₀ heterocyclyl wherein the heteroatoms are independently selected from N, O and S; C₁-C₁₀ alkyloxy; amino; C₁-C₁₀ alkylamino; COR⁶; CONR⁶R⁷; and COOR⁶;

R^6 and R^7 are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S;

as well as of pharmaceutically acceptable salts or prodrugs thereof, for preparing a medication for the treatment of a disorder selected from hyperproliferative diseases, autoimmune diseases and heart diseases.

2. The use according to claim 1, wherein the disorder is a cancer.

3. A compound of formula (I)



(I)

wherein

(i) R^1 and R^2 are the same or different and are selected from H, $-\text{CH}_2-\text{O}-\text{CO}-R^5$, $-\text{CH}_2-\text{O}-\text{CO}-\text{NR}^4R^5$ and $-\text{CH}_2-\text{O}-\text{CO}-\text{OR}^5$;

R^3 is $=\text{O}$, $=\text{S}$ or $=\text{NR}^5$;

R^4 and R^5 are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; substituted or non-substituted benzyl; substituted or non-substituted mono- or bicyclic aryl; substituted or non-substituted mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or R^4 and R^5 in $-\text{CH}_2-\text{NR}^4R^5$ are bonded together and form, together with the nitrogen atom to which they are bonded, a substituted or non-substituted non-aromatic C1-C10 mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups; with the proviso that R^1 and R^2 are not both H; or


(ii) R^1 and R^2 together with the carbon atom to which they are bonded form a substituted or non-substituted cyclic carbonate;

wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR⁶; CONR⁶R⁷; and COOR⁶;

R⁶ and R⁷ are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S;

as well as pharmaceutically acceptable salts or prodrugs of the compounds of formula (I).

4. A process for the preparation of a compound according to claim 3 by reacting a compound of formula (I)



(I)

wherein


R¹, R² and R³ are as defined in claim 3, provided that at least one of R¹ and R² is -CH₂OH; or wherein both R¹ and R² are -CH₂OH and R³ is as defined in claim 3; under conditions suitable for transforming at least one of R¹ and R² into -CH₂-O-CO-R⁵, -CH₂-O-CO-NR⁴R⁵ or -CH₂-O-CO-OR⁵ wherein R⁴ and R⁵ are as defined in claim 3.

5. A compound according to claim 3 for use as a medicament.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 3, or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable excipient.

7. A pharmaceutical composition according to claim 6, comprising at least one further, pharmaceutically active compound.

8. A pharmaceutical composition according to claim 7, wherein the compound according to claim 3 and the further active compounds provide a synergistic therapeutic effect.
9. A pharmaceutical composition according to claim 8, wherein the at least one further active compound *in vivo* is susceptible of reacting with glutathione.
10. A pharmaceutical composition according to any of claims 7-9, wherein the further pharmaceutically active compound is selected from adriamycin, melphalan and cisplatin.
11. A method of treatment of a disease selected from hyperproliferative diseases, autoimmune diseases, and heart diseases by administration of a therapeutically effective amount of a compound of formula (I)



(I)

wherein

- (i) R¹ and R² are the same or different and are selected from H, -CH₂-O-R⁵, -CH₂-O-SO₂-R⁵, -CH₂-S-R⁵, -CH₂-NR⁴R⁵, -CH₂-O-CO-R⁵, -CH₂-O-CO-NR⁴R⁵ and -CH₂-O-CO-OR⁵;
- R³ is =O, =S or =NR⁵;
- R⁴ and R⁵ are the same or different and are selected from H; substituted or non-substituted, unbranched or branched, saturated or unsaturated C₃-C₁₂ cycloalkyl or C₁-C₁₀ alkyl; substituted or non-substituted benzyl; substituted or non-substituted mono- or bicyclic aryl; substituted or non-substituted mono-, bi- or tricyclic C₁-C₁₀ heteroaryl or non-aromatic C₁-C₁₀ heterocyclyl wherein the heteroatoms are independently selected from N, O and S; or R⁴ and R⁵ in -CH₂-NR⁴R⁵ are bonded together and form, together with the nitrogen atom to which they are bonded, a substituted or non-substituted non-aromatic C₁-C₁₀ mono- or bicyclic heterocyclyl optionally containing one or several further heteroatoms independently selected from N, O and S and optionally comprising one or several cyclic keto groups; with the proviso that when R¹ and R² are both -CH₂-OR⁵ then R⁵ is not H; and

with the further proviso that when one of R^1 and R^2 is H and the other one is $-CH_2-NR^4R^5$, then R^4 and R^5 are not substituted or non-substituted monocyclic aryl; or

(ii) R^1 and R^2 together with the carbon atom to which they are bonded form a substituted or non-substituted cyclic carbonate;

wherein the substituents of the substituted groups are selected from unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; halogen; mono- or bicyclic aryl; mono-, bi- or tricyclic C1-C10 heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S; C1-C10 alkyloxy; amino; C1-C10 alkylamino; COR^6 ; $CONR^6R^7$; and $COOR^6$;

R^6 and R^7 are the same or different and are selected from H; unbranched or branched, saturated or unsaturated C3-C12 cycloalkyl or C1-C10 alkyl; benzyl; mono- or bicyclic aryl; mono-, bi- or tricyclic heteroaryl or non-aromatic C1-C10 heterocyclyl wherein the heteroatoms are independently selected from N, O and S;

as well as of pharmaceutically acceptable salts or prodrugs thereof, to a patient in the need of such treatment.

12. The method according to claim 11 wherein the compound of formula (I) is administered together with a further, pharmaceutically active compound.

13. The method according to claim 12, wherein the compound of formula (I) and the further, pharmaceutically active compound are providing a synergistic effect *in vivo*.

14. The method according to the claim 13 wherein the further, pharmaceutically active compound *in vivo* is susceptible of reacting with glutathione.

15. The method according to any of the claims 12-14, wherein the further pharmaceutically active compound is selected from adriamycin, melphalan, cisplatin.

1/6

% cell death





Figure 1

% cell death





Figure 2

2/6





Figure 3





Figure 4

4/6

% cell death





Figure 7

% cell death





Figure 8

5/6

% cell death





Figure 9

% cell death





Figure 10

6/6

% cell death






Figure 11



(I)